Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo, Pankil K. Shah, Natacha Bordry, Robert D. Hudson, Brenna Albracht, Mariagrazia Di Marco, Virginia Kaklamani, Pierre Yves Dietrich, Barbara S. Taylor, Pierre Francois Simand, Darpan Patel, Jing Wang, Intidhar Labidi-Galy, Sara Fertani, Robin J. Leach, Jose Sandoval, Ruben Mesa, Kate Lathrop, Nicolas Mach, Dimpy P. Shah

Producción científica: Articlerevisión exhaustiva

180 Citas (Scopus)

Resumen

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.

Idioma originalEnglish (US)
Páginas (desde-hasta)1091-1098.e2
PublicaciónCancer Cell
Volumen39
N.º8
DOI
EstadoPublished - ago 9 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer'. En conjunto forman una huella única.

Citar esto